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The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin- but not
fasting-induced neuronal activation in the hypothalamic arcuate
nucleus
Abstract
The hypothalamic arcuate nucleus (Arc) is the presumed target site for the orexigenic hormone ghrelin
which is secreted from the stomach during fasting. Ghrelin directly activates Arc neurones. Similar to
exogenous ghrelin, overnight food deprivation also induces c-Fos expression in the Arc of mice. In this
study we tested the role of endogenous ghrelin in the fasting-induced c-Fos expression in the Arc of
mice. We used NOX-B11-3, the latest generation of the recently developed ghrelin-binding compounds,
so-called RNA Spiegelmers (SPM) to block endogenous ghrelin action during food deprivation. The
specificity and potency of this compound was also tested in electrophysiological and
immunohistological experiments. In electrophysiological in vitro single cell recordings NOX-B11-3
effectively blocked the excitatory effect of ghrelin in the medial Arc (ArcM) of rats while the
biologically inactive control SPM had no effect. Furthermore, NOX-B11-3 (15 mg/kg ip) potently
suppressed ghrelin-induced (25 µg/kg sc, 12h after SPM injection) c-Fos expression in the Arc.
However, the same dose of NOX-B11-3 when injected at the beginning of a 14h fasting period had no
effect on the c-Fos expression in the Arc of mice. These results demonstrate that NOX-B11-3 is a long
acting compound, which effectively blocks the effect of exogenous ghrelin on neuronal activity in the
Arc under in vitro and in vivo conditions. Furthermore, increased ghrelin signalling does not appear to
be a necessary factor for the activation of Arc neurones during food deprivation or other fasting-related
signals might have masked or compensated the loss of the ghrelin effect.
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 Abstract 
The hypothalamic arcuate nucleus (Arc) is the presumed target site for the orexigenic 
hormone ghrelin which is secreted from the stomach during fasting. Ghrelin directly 
activates Arc neurones. Similar to exogenous ghrelin, overnight food deprivation also 
induces c-Fos expression in the Arc of mice. In this study we tested the role of 
endogenous ghrelin in the fasting-induced c-Fos expression in the Arc of mice. We used 
NOX-B11-3, the latest generation of the recently developed ghrelin-binding compounds, 
so-called RNA Spiegelmers (SPM) to block endogenous ghrelin action during food 
deprivation. The specificity and potency of this compound was also tested in 
electrophysiological and immunohistological experiments. In electrophysiological in 
vitro single cell recordings NOX-B11-3 effectively blocked the excitatory effect of 
ghrelin in the medial Arc (ArcM) of rats while the biologically inactive control SPM had 
no effect. Furthermore, NOX-B11-3 (15 mg/kg ip) potently suppressed ghrelin-induced 
(25 µg/kg sc, 12h after SPM injection) c-Fos expression in the Arc. However, the same 
dose of NOX-B11-3 when injected at the beginning of a 14h fasting period had no effect 
on the c-Fos expression in the Arc of mice. These results demonstrate that NOX-B11-3 is 
a long acting compound, which effectively blocks the effect of exogenous ghrelin on 
neuronal activity in the Arc under in vitro and in vivo conditions. Furthermore, increased 
ghrelin signalling does not appear to be a necessary factor for the activation of Arc 
neurones during food deprivation or other fasting-related signals might have masked or 
compensated the loss of the ghrelin effect. 
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Introduction 
Ghrelin is a 28 amino acid peptide hormone, secreted predominantly from the endocrine 
cells of the stomach (1). Plasma levels of ghrelin are modulated by the nutritional state. 
During fasting and shortly before meals circulating ghrelin concentrations are elevated, 
while feeding or glucose intake reduce circulating ghrelin levels (2,3,4,5,6). Central or 
peripheral ghrelin administration stimulates food intake and body weight gain both in 
rodents and humans (7,8,9,10). Neutralising circulating or central ghrelin has the opposite 
effect in rats (7,11,12). Thus, ghrelin has been postulated to be an important peripheral 
orexigenic signal that regulates ingestive behaviour and energy balance.  
Ghrelin is the endogenous ligand of the growth hormone secretagogue receptor type 1a 
(GHS-R 1a,) which is densely expressed in the hypothalamic arcuate nucleus (Arc) 
(13,14). Specific downregulation of GHS-R expression in the Arc by antisense riboprobes 
reduced food intake and body weight gain in rats (15). The orexigenic effect of synthetic 
growth hormone secretagogues (GHS) was also abolished in these animals, again arguing 
for an Arc mediation of ghrelin’s orexigenic action.  
In electrophysiological studies ghrelin (16,17) and GHS (18) activated the Arc neurones 
by a direct, postsynaptic action. Furthermore, ghrelin and GHS administration induce c-
Fos expression, a marker of neuronal activation in the orexigenic neuropeptide Y (NPY) 
neurones in the Arc (7,19,20). Hence, NPYergic Arc neurones are considered as a central 
target site for circulating ghrelin. 
Interestingly, c-Fos expression is induced in the Arc of food deprived mice (21,22), i.e. 
when ghrelin levels are high. Furthermore, the fasting-induced activation of Arc neurones 
seems to occur mainly in NPYergic neurones (23). Thus, it is plausible that elevated 
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ghrelin levels during fasting contribute to the induction of c-Fos expression in Arc 
neurones of mice. However, due to the lack of specific ghrelin antagonists this has not 
been investigated so far. 
Recently a new class of L-RNA-based hormone antagonists, so-called Spiegelmers 
(SPMs), has been developed. Unlike classic hormone antagonists, SPMs do not interact 
with the receptor, but bind with high affinity to their target molecule and therefore block 
their biological effect by preventing binding to the endogenous receptor. The anti-ghrelin 
SPM, NOX-B11 is highly specific for the bioactive n-octanoylated form of ghrelin (24). 
NOX-B11 potently and specifically blocked the biological effects of exogenous ghrelin, 
e.g. the stimulation of growth hormone secretion, food intake and body weight gain 
(24,25,26). In the current study we used the latest generation of the anti-ghrelin SPMs 
(NOX-B11-3) which shows a 5-fold higher ghrelin binding potency than the original 
NOX-B11 compound (27). In our studies we first tested the potency and specificity of 
this new compound under our experimental conditions. Using in vitro extracellular single 
unit recordings and in vivo c-Fos immunohistochemistry, we investigated whether NOX-
B11-3 blocks the excitatory effect of ghrelin on Arc neurones. Second, we explored in 
immunohistological c-Fos studies whether endogenously released ghrelin contributes to 
the activation of Arc neurones during fasting in mice.  
 
Material and Methods 
Spiegelmers 
NOX-B11-3 is a 44 nucleotide L-RNA, containing a hexaethylene glycol linker (L) with 
the sequence 5’-GCGUAAGACCGAAGGUAACCAAUCCUACCG---L---
 5 
CGGUGAGGCAGCAC-3’. It is a derivative of Spiegelmer NOX-B11 and its selection 
has been described previously (27). The biologically inactive control Spiegelmer (cSPM) 
has the sequence 
5’UAAGGAAACUCGGUCUGAUGCGGUAGCGCUGUGCAGAGCU-3’. Spiegelmers 
used in the in vivo studies were modified with a 40 kD polyethylene glycol (PEG) moiety 
to delay renal excretion. All Spiegelmers were synthesised at NOXXON Pharma AG.  
All animal procedures were approved by the Veterinary Office of the Canton Zurich. 
 
Electrophysiological studies 
In contrast to mice, NPY and POMC neurons are regionally clustered in rats in the medial 
and lateral subregions of the Arc respectively, which makes it easier to specifically target 
these cells in our electrophysiological approach. Furthermore, in our previous 
electrophysiological studies characterizing the neuronal effects of ghrelin have all been 
conducted in rats, thus in order to ensure compatibility between our studies we used rats 
in the present experiments as well. Male adult Wistar rats (200-250g) were used, which 
had ad libitum access to standard laboratory rat chow (#3430, Kliba Nafag AG, 
Switzerland) and water. All animals were maintained in a temperature-controlled room 
on an artificial 12 h dark-light cycle (21 ± 1 °C, lights on at 6.00 am). The experimental 
procedures for the extracellular recordings were the same as previously described (17,28). 
Rats were decapitated, their brains were quickly removed and superfused with modified 
ice-cold artificial cerebrospinal fluid (aCSF) of the following composition (in mM): NaCl 
124; KCl 5; NaH2PO4 1.2; MgSO4 1.3; CaCl2 1.2; NaHCO3 26; glucose 10, equilibrated 
with 95% O2 and 5% CO2, pH 7.4; 290 mosm/kg. 400 µm thick coronal whole brain 
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slices at the mid rostro-caudal level of the Arc were cut using a custom made vibratome. 
A rectangular (2x2 mm) piece of tissue containing the Arc was dissected by hand and 
transferred to a temperature controlled (37.0°C) recording chamber constantly superfused 
with pre-warmed aCSF at a rate of 1.6 ml/min.  
Extracellular recordings were obtained from neurones of the ArcM using glass-coated 
platinum-iridium electrodes. According to the neuroanatomical brain map of Paxinos and 
Watson (29), the recorded neurones were located within a distance of 300 µm lateral to 
the third ventrical wall and were thus defined as “ventromedial” Arc neurones (17). 
Ghrelin (Bachem, Switzerland) was applied at a concentration of 10-8 M, which has been 
shown to represent an effective dose without causing receptor desensitization (16,17). 
After a stable recording from a single neurone had been established ghrelin was 
superfused in combination with cSPM, with NOX-B11-3 (both 25 x 10-8 M) or without 
any SPM compound. All cells were tested with all three stimuli. To facilitate the binding 
between ghrelin and SPMs, ghrelin was co-incubated with the SPMs 15 min at room 
temperature prior to superfusion. When superfused alone, ghrelin was kept under the 
same conditions without SPM. In order to exclude that the SPMs cause any changes in 
the firing rate, control superfusions of these substances (25 x 10-8 M) were carried out 
without ghrelin. Only ghrelin responsive neurones were included in the analysis. From all 
continuously recorded rate meter counts, the average discharge rate of each neurone was 
evaluated for 60 seconds prior each stimulus. This value (spontaneous discharge rate) was 
used to normalise changes in the firing rate, expressed as % change of the spontaneous 
discharge rate. If the averaged change of discharge rate during the response was larger 
than 20%, the neurone was considered sensitive to the applied stimulus. In addition to the 
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mean change of the discharge rate during the entire responses, the peak values of the 
responses were calculated on a basis of a 30 s interval during which the firing rate was 
maximal. Finally, the duration between the application of the drugs and the onset of the 




c-Fos expression is only upregulated in the Arc of mice during fasting, but not in rats, at 
least during a moderate food deprivation, thus we used mice in the immunohistological 
studies. Adult male C57Bl/6N (Charles Rivers, Germany) mice, housed in individual 
cages in a temperature-controlled room (21 ± 1 °C) were used. The mice were kept under 
a 12 h light/dark cycle (lights off 9 am). They had free access to rodent chow and water, 
except in the food deprivation study, when animals were fasted for 14h. All animals were 
handled daily for at least three weeks before the experiments, according to the procedure 
recommended by Ryabinin et al. (30) which has been shown to reduce handling- and 
injection-induced c-Fos expression.  
 
Experimental procedure  
Twenty mice which had ad libitum access to food during the studies were randomly 
assigned to one of four experimental groups (n=5). On the day of the experiment two 
groups received an intraperitoneal injection of the biologically inactive cSPM at the 
beginning of the light phase (9pm). The other two groups received NOX-B11-3 
(15mg/kg; 10ml/kg in saline). Twelve hours after Spiegelmer application (i.e. at the 
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beginning of the dark phase) one cSPM and one NOX-B11-3 treated group received a 
ghrelin injection (25 µg/kg sc), while the other two groups received a saline (10ml/kg sc). 
Mice were sacrificed 2h after ghrelin or saline injection (11am, i.e. 2h into the dark 
phase). Two additional groups of mice (n=5) were food deprived at the beginning of the 
light phase (9pm) and received a cSPM or NOX-B11-3 injection at this time point. These 
mice remained fasted without any further treatment until sacrifice 14h later (11am).  
 
Immunohistochemistry 
Detection of c-Fos immunoreactive neurones in the Arc has been described previously 
(28). Briefly, animals were deeply anaesthetised with pentobarbital (Nembutal, Abbott 
Laboratories USA 0.1 ml/mouse ip) and perfused transcardially with phosphate buffer 
(PB 0.1M), followed by 4% paraformaldehyde (in 0.1M PB). The brains were removed, 
postfixed for 2h in the same fixative, cryoprotected in 20 % sucrose solution (in 0.1M 
PB) for 48h and snap frozen in CO2. Coronal sections (20 µm) were cut in a cryostat (CM 
3050 Leica, Nussloch, Germany) and every second hypothalamic section was thaw 
mounted on microscopic glass slides (SuperFrost Plus, Faust, Schaffhausen Switzerland). 
After air-drying at room temperature and rehydrating in phosphate buffered saline (PBS), 
sections were incubated in blocking solution for 2h (1.5% rabbit normal serum + avidin, 
Vector Laboratories). The primary antibody (polyclonal goat anti-c-Fos, Santa Cruz; 
1:10’000 + biotin, Vector Laboratories) was applied for 48 hours at 4° C. The unbound 
antibody was removed by washing in PBS before the sections were incubated with the 
secondary antibody (biotinylated rabbit-anti-goat, Vectastain®-Elite ABC Kit, Vector 
Laboratories; 1:200) for 2 hours at room temperature. After incubation in ABC solution 
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(Vectastain®-Elite ABC Kit, Vector Laboratories) DAB was used as a chromogen [0.04% 
in PBS with 0,02% H2O2 and for colour enhancement 0.08% NiCl2 (x 6 H2O), 0.01% 
CoCl2 (x 6 H2O)]. Finally, the sections were dehydrated in graded alcohols, cleared in 
xylenes and coverslipped with Entellan (Merck, Darmstadt, Germany). 
The localization of c-Fos expressing neurones was identified according to the mouse 
brain atlas by Hof et al. (31). For each animal c-Fos positive cells were counted manually 
and in a blinded fashion in eleven corresponding sections of the Arc bilaterally, in an area 
within 150 µm from the wall of the third ventricle. The mean value of the cell 
counts/section of an individual animal was used for statistical analyses. Representative 
photomicrographs were taken by a digital camera (AxioCam, Carl Zeiss AG). 
 
Ghrelin levels 
Ghrelin levels were measured at 11 am in ad libitum fed (n=3) and 14h fasted mice (n=5) 
in a separate experiment. Mice were anesthetised with pentobarbital as described in the c-
Fos studies and blood was collected into EDTA coated tubes by cardiac puncture. Plasma 
total ghrelin levels were analyzed by RIA (Linco Research). Unfortunately, direct 
analytical assessment of the inactivation of ghrelin in the plasma is limited, because 
immunoassays do not distinguish SPM-bound from unbound ghrelin. For this reason 
SPM treated groups could not be included in these studies. 
 
Statistics 
The electrophysiological data were analyzed by one way ANOVA on ranks for repeated 
measurements, followed by Student-Newman-Keuls post-hoc test. In the 
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immunohistological studies group means were compared by Student’s t-test or by two 
way ANOVA, followed by Student-Newman-Keuls post-hoc test. P<0.05 was considered 




Nine single unit recordings from ghrelin-excited neurones, located in the ArcM and 
presumably containing NPY, were obtained from 9 different slice preparations. 
Superfusion of ghrelin alone or in combination with the cSPM resulted in reversible 
excitatory responses (Figure 1A; Table 1). The mean excitatory effect of ghrelin in 
combination with cSPM was not different from the mean excitatory action induced by 
ghrelin alone (Table 1). However, co-application of NOX-B11-3 effectively blocked the 
ghrelin-induced activation in the ArcM (p<0.05) (Figure 1A; Table1). When applying the 
general criteria of an excitatory effect as outline above, 1 of the 9 neurones was excited 
by ghrelin in the presence of NOX-B11-3. However, the mean increase in the discharge 
rate in this neurone was 73% smaller when compared to the co-application of ghrelin and 
cSPM (1.7 vs. 6.3 Hz). All mean effect parameters for the different stimuli are 
summarised in Table 1. Notably, all effect parameters were significantly lower following 
the combined superfusion with NOX-B11-3 and ghrelin compared to the other two 
stimuli. Neither cSPM (n=4) nor NOX-B11-3 (n=3) affected neuronal activity when 




Influence of SPMs on ghrelin-induced c-Fos expression in the Arc  
Ad libitum fed, saline injected animals showed hardly any c-Fos positive cells in the Arc, 
irrespective of NOX-B11-3 or cSPM pretreatment. Compared to saline injected animals, 
ghrelin significantly increased the number of c-Fos immunoreactive cells in the Arc of 
cSPM treated mice (p<0.001), but not in the NOX-B11-3 pretreated animals (Figure 2). 
Two way ANOVA revealed a significant main effect of NOX-B11-3 (p<0.01) and 
ghrelin (p<0.001) treatment and a significant interaction between NOX-B11-3 and 
ghrelin injection (p<0.05) in the ad libitum fed animals.  
 
Influence of SPMs on fasting-induced c-Fos expression in the Arc  
Fasted mice had 5 fold higher blood ghrelin levels (8.3 ±0.8 ng/ml) compared to ad 
libitum fed mice (1.4 ± 0.3 ng/ml; p=0.001).  
Fasting produced strong c-Fos expression in the Arc of mice. The number of c-Fos 




The orexigenic effect of ghrelin, the only peripheral orexigenic peptide known to date, is 
presumably mediated via Arc neurones. We investigated whether the increase in plasma 
ghrelin concentrations and the parallel increase in c-Fos expression in the Arc of fasted 
mice might be causally linked. Although ghrelin concentrations rose 5 fold in the fasted 
mice, the anti-ghrelin Spiegelmer NOX-B11-3, had no effect on the fasting-induced c-Fos 
expression in the Arc. This suggests that an increase in circulating ghrelin does not seem 
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to be a decisive factor for the fasting-induced neuronal activation in the Arc. As shown in 
our electrophysiological and immunohistological studies NOX-B11-3 potently and 
specifically blocked the excitatory effect of exogenous ghrelin on Arc neurones.  
The SPMs directly bind to their target molecules and thus neutralise their effects. Such an 
interaction minimises the risk of undesired side effects, e.g. partial agonistic action that is 
a common phenomenon for numerous receptor antagonists, particularly when used at 
higher doses. In our studies we did not find any indication for agonistic effects of the 
SPMs. When applied alone neither the inactive cSPM nor NOX-B11-3 caused any 
changes in firing rate and c-Fos expression was minimal in mice treated with cSPM and 
NOX-11B-3 alone. Furthermore, there was no detrimental impact of NOX-B11-3 on 
neuronal function as shown by the undisturbed responsiveness to ghrelin after washout of 
the drug.  
 
In previous electrophysiological studies we characterised the effect of the GHS-R 
antagonist (D-Lys3)-GHRP-6 under the same experimental conditions (16). Even in 
1000-fold excess this compound only weakly antagonised the ghrelin-induced responses. 
Compared to this very low potency, NOX-B11-3 was clearly superior because it almost 
completely blocked the ghrelin-induced excitation when used in only 25 fold molar 
excess. 
 
Spiegelmers are L-isomer oligonucleotides which are not degraded by endogenous 
nucleases. Hence, SPMs are unusually stable in biological fluids (over 60 hrs) (32), 
allowing a long-lasting peptide neutralisation after single application. This makes these 
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compounds very useful for experimental purposes and possibly as therapeutic agents. Our 
c-Fos studies are consistent with a long-lasting effect, because NOX-B11-3 abolished the 
neuronal effects of exogenous ghrelin in the Arc when applied 12h before a ghrelin 
stimulus. These results provide evidence that the lack of NOX-B11-3 effect on the 
fasting-induced activation of Arc neurones was not due to the loss of effect during the 
time between injection and sacrifice. Rather, our data argue against a dominant 
contribution of endogenous ghrelin to the fasting-induced activation in the Arc. 
Nevertheless, based on our results a stimulatory effect of circulating ghrelin on Arc 
neurons cannot be completely excluded. It is plausible that other fasting-related signals 
could have compensated for the loss of ghrelin’s effect in the NOX-B11-3 treated fasted 
mice. However, the identity of these factors, which might be involved in the activation of 
the Arc during food deprivation, remains unknown at this point.  
The Arc is a receptive site for various peripheral signals, the blood levels of which 
change according to the feeding status, including glucose, leptin, insulin and 
corticosterone. These factors are likely candidates to modulate Arc activity during 
fasting. The Arc contains glucosensitive neurones, (for reviews see 33,34) and the 
orexigenic NPY neurones are excited (35,36) and increase c-Fos expression (37,38) when 
glucose level decrease. Lean fasted mice have a blood glucose level about 30% below 
that of ad libitum fed mice under our experimental conditions (unpublished observation). 
Thus, it is plausible that fasting-induced hypoglycaemia might have contributed to the c-
Fos expression in the Arc. This would be consistent with our observations that a 
peripheral injection of glucose effectively reverses the fasting-induced activation in Arc 
neurones (39).  
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Insulin and leptin are considered two of the most important peripheral signals involved in 
the long-term regulation of energy balance and body weight. Both peptides have well-
established inhibitory effects on orexigenic Arc neurones and the blood level of both 
decreases in fasted animals (40). Therefore it is plausible that during fasting a 
disinhibition of these neurones occurs, which then either per se may induce c-Fos 
expression or may facilitate the action of other fasting-related signals in the Arc. 
 
In addition to humoral signals, the Arc receives neuronal inputs that convey information 
reflecting the energy status. The NPY neurones receive excitatory projections form the 
orexin containing neurones (41,42) located in the lateral hypothalamic area (43, 44). 
Orexins stimulate food intake and their expression is upregulated during fasting (45). 
Hence, it is conceivable that Arc-intrinsic orexin release might contribute to the neuronal 
activation in the Arc during food deprivation. Furthermore, recent studies suggest a role 
for hindbrain projections to the hypothalamus in the control of food intake and in the 
mediation in ghrelin’s neuronal and behavioural effects (46).  
 
The physiological impact of neuronal activation in the Arc during fasting is not yet 
known. Many of the NPY containing neurones have been shown to express c-Fos in the 
fasted state (23) and it is commonly accepted that an activation of these cells stimulates 
food intake (40). Arc neurones, especially NPY neurones, are however involved in the 
regulation of several neuroendocrine functions as well, which induce adaptive responses 
to starvation via controlling growth, gonadal, adrenal and thyroid function. In fasted 
animals non-vital functions are inhibited: growth hormone secretion is reduced, in female 
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mice oestrus cycle is delayed, in male mice testosterone levels are severely reduced (47). 
Furthermore, thyroid hormone concentrations are decreased while glucocorticoid levels 
are increased (47). Similar responses were reported in human subjects (48). Thus the 
activation in the Arc neurones, besides enhancing energy repletion when food is 
available, might also be involved in the re-partitioning of endogenous energy sources 
during fasting and in the reduction energy expenditure.  
 
In summary our study provides in vitro electrophysiological and in vivo 
immunohistochemical evidence that the recently developed L-RNA Spiegelmer, NOX-
B11-3 is a potent and specific ghrelin antagonist, which exerts a long-lasting action after 
a single peripheral administration. Based on these results the persistence of fasting-
induced c-Fos expression in the Arc of NOX-B11-3 treated mice argues against a 
predominant contribution of endogenous ghrelin to the stimulation of Arc neurones 
during food deprivation. Hence, the sum of other fasting-related signals, possibly a drop 
in glucose, insulin and leptin concentrations, may be sufficient to activate the Arc. Which 
of these factors plays the predominant role in this process awaits further clarification.  
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Figure 1. Electrophysiological single unit recordings of ghrelin-sensitive neurones 
located in the medial arcuate nucleus (rat). A: In contrast to the inactive control 
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Spiegelmer (cSPM) the ghrelin antagonist NOX-B11-3 effectively blocked the ghrelin-
induced excitation. Stimulation with ghrelin alone induced a similar excitatory effect as 
ghrelin in combination with cSPM. B: Neither the inactive control Spiegelmer nor the 





Figure 2. Anti-ghrelin Spiegelmer NOX B11-3, but not biologically inactive control 
Spiegelmer (cSPM) completely blocked ghrelin-induced c-Fos expression in the arcuate 
nucleus (Arc) of ad libitum fed mice. Representative Arc sections immunostained for c-
Fos of mice pretreated with NOX-B11-3 (15 mg/kg, ip) or cSPM. 12h after SPM 
injection mice received a ghrelin (25 µg/kg sc) or saline injection (n=5/group). Bar charts 
show the number of c-Fos positive neurons in the Arc of the different treatment groups. 
Different letters indicate significant differences between the groups (ANOVA; p<0.05). 





Figure 3. The anti-ghrelin Spiegelmer NOX B11-3 (15 mg/kg, ip) had no effect on c-Fos 
expression in the Arc of 14h fasted mice. Representative Arc sections immunostained for 
c-Fos of mice pretreated with NOX-B11-3 (15 mg/kg, ip) or biologically inactive control 
Spiegelmer (cSPM). At the time of injections mice were food deprived and remained 
fasted until sacrifice 14h later. Bar charts show the number of c-Fos positive neurons in 
the Arc of the different treatment groups. (n=5/group; Student’s t-test). 3V:3rd ventricle, 
Scale bar: 100 µm. 
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Table 1:  
 
Table 1: Effect parameters of the electrophysiological responses induced by ghrelin (10-8 
M) in the medial arctue nucleus (rat) when superfused alone and in combination with 
inactive control Spiegelmer (cSPM) or the anti-ghrelin Spiegelmer NOX-B11-3 (both 25 
x 10-8 M). NOX-B11-3 significantly blocked the ghrelin-induced excitatory response 
compared to superfusion of ghrelin alone or in combination with the cSPM. Different 
letters indicate significant differences (one-way ANOVA; p<0.05). Values are means ± 
SEM.  
Effect parameter ghrelin + cSPM  
(n=9) 




Mean latency [s]       106 ± 16 a              43 ± 10 b      102 ± 22 a 
Mean response [%]         85 ± 16 a                8 ± 4 b        91 ± 20 a 
Mean response [Hz]        2.6 ± 0.6 a             0.4 ± 0.2 b       2.5 ± 0.5 a 
Mean peak response [Hz]        4.6 ± 1.2 a             1.0 ± 0.4 b       4.5 ± 1.1 a 
Mean response duration [s]       894 ± 122 a            409 ± 69 b      921 ± 141 a 
